Shiraz Ladiwala's most recent trade in Mesa Laboratories, Inc. was a trade of 1,574 Common Stock done . Disclosure was reported to the exchange on Sept. 1, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mesa Laboratories, Inc. | Shiraz S. Ladiwala | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 1,574 | 3,074 (0%) | 0% | 0 | Common Stock | |
| Mesa Laboratories, Inc. | Shiraz S. Ladiwala | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 1,574 | 0 | - | - | Restricted Stock Units - 4 | |
| Mesa Laboratories, Inc. | Shiraz S. Ladiwala | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 1,949 | 1,949 | - | - | Restricted Stock Units - 5 | |
| Mesa Laboratories, Inc. | Shiraz Ladiwala | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 1,055 | 0 | - | - | Restricted Stock Units - 2 | |
| Mesa Laboratories, Inc. | Shiraz Ladiwala | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 1,055 | 1,460 (0%) | 0% | 0 | Common Stock | |
| Mesa Laboratories, Inc. | Shiraz Ladiwala | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2022 | 40 | 40 | - | - | Restricted Stock Units - 3 | |
| Mesa Laboratories, Inc. | Shiraz Ladiwala | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 1,055 | 1,055 | - | - | Restricted Stock Units - 2 | |
| Mesa Laboratories, Inc. | Shiraz Ladiwala | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2022 | 405 | 405 (0%) | 0% | 0 | Common Stock | |
| Mesa Laboratories, Inc. | Shiraz Ladiwala | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2022 | 405 | 0 | - | - | Restricted Stock Units - 1 | |
| Mesa Laboratories, Inc. | Shiraz Ladiwala | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 405 | 0 | - | - | Restricted Stock Units - 1 |